Chronic Spinal Cord Injury Impairs Primary Antibody Responses but Spares Existing Humoral Immunity in Mice

Michael A. Oropallo, Katherine S. Held, Radhika Goenka, Sifat A. Ahmad, Patrick J. O’Neill, Oswald Steward, Thomas E. Lane and Michael P. Cancro

*J Immunol* 2012; 188:5257-5266; Prepublished online 20 April 2012; doi: 10.4049/jimmunol.1101934

http://www.jimmunol.org/content/188/11/5257

**Supplementary Material** http://www.jimmunol.org/content/suppl/2012/04/20/jimmunol.1101934.DC1

**References** This article cites 51 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/188/11/5257.full#ref-list-1

**Subscription** Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

**Permissions** Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Chronic Spinal Cord Injury Impairs Primary Antibody Responses but Spares Existing Humoral Immunity in Mice

Michael A. Oropallo,*1 Katherine S. Held,†1 Radhika Goenka,*1 Sifat A. Ahmad,*1 Patrick J. O’Neill,* Oswald Steward,†3,5 Thomas E. Lane,†,4,1,6,7 Michael P. Cancro*

Spinal cord injury (SCI) results in immune depression. To better understand how injury inhibits humoral immunity, the effects of chronic thoracic SCI on B cell development and immune responses to thymus-independent type 2 and thymus-dependent Ags were determined. Mice received complete crush injury or control laminectomy at either thoracic level 3, which disrupts descending autonomic control of the spleen, or at thoracic level 9, which conserves most splenic sympathetic activity. Although mature B cell numbers were only mildly reduced, bone marrow B cell production was transiently but profoundly depressed immediately after injury. Despite the return of normal B cell production 4 wk after SCI, mice receiving thoracic level 3 injury showed a significant reduction in their ability to mount primary thymus-independent type 2 or thymus-dependent immune responses. The latter were marked by decreases in germinal center B cells as well as class-switched high-affinity Ab-secreting cells. Importantly, injury did not affect affinity maturation per se, pre-existing B cell memory, or secondary humoral immune responses. Taken together, these findings show that chronic high thoracic SCI impairs the ability to mount optimal Ab responses to new antigenic challenges, but spares previously established humoral immunity.


Bacterial infections are the leading cause of death among patients who survive spinal cord injury (SCI), reflecting generalized immune depression (1, 2). These observations suggest that SCI impairs humoral immunity via multiple mechanisms, including dysregulation of both the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system (SNS). For example, corticosteroids secreted by the HPA axis following stress or injury can diminish B cell lymphopoiesis (3). Furthermore, norepinephrine secreted by SNS nerves, which innervate lymphoid organs, can bind to B cells and influence their responsiveness (4–8). Accordingly, assessment of how SCI per se, as well as accompanying dysregulation of the HPA axis and/or SNS, contributes to these effects is of particular clinical interest.

Studies using murine models of SCI have begun to dissect the relative roles played by loss of splenic sympathetic regulation versus increased injury-induced stress hormones in perturbations of B cell homeostasis and function. Acute injury at thoracic level 3 (T3), which disrupts autonomic control of the spleen, results in fewer total splenic B cells and impaired thymus-dependent (TD) Ab responses (9, 10). Dysregulation of the SNS was implicated in these alterations, as blocking of SNS-derived norepinephrine signaling restored TD Ab responses in T3-injured mice and was intact in both laminectomy controls and mice injured at T9, a level at which most central sympathetic regulation to the spleen is conserved (9). Although these findings show that acute SCI disrupts primary TD humoral responses, the question remains whether these effects persist during chronic injury. Moreover, it is unclear whether these findings reflect generalized shifts in the numbers or functional capacities of all B lineage cells, or instead differentially impact particular B cell subsets and their associated functions. Furthermore, as patients are most often severely affected by pathogens that characteristically elicit thymus-independent (TI) humoral responses (2), it is essential to know how SCI affects primary TI responses. Finally, whether the processes required to generate high-affinity Abs during primary TD responses are intact, as well as whether pre-existing memory B cell numbers and responses are retained, is unknown.

Accordingly, to further understand how SCI affects B cell maintenance, responsiveness, and memory, we have conducted detailed assessments of B cell subsets and function in mice receiving complete crush SCI at either T3 or T9. We show that previously observed reductions in splenic B cells during acute SCI...
reflect cessation of B lymphopoiesis, since developing bone marrow (BM) B cell subsets and transitional (TR) B cells were profoundly reduced 8 d after SCI. Blunted B cell genesis is transient, as developing BM subsets were completely restored to preinjury levels after 28 d. Furthermore, mature follicular (FO) B cells, but not marginal zone (MZ) B cells, were reduced following injury. Evaluation of Ag-specific B cell responses during chronic injury revealed that the magnitude of both TI and primary TD responses were reduced in T3 injured mice. Finally, we show that SCI impacts neither memory B cell numbers nor the ability to mount anamnestic responses to Ags encountered prior to injury.

Taken together, our findings reveal that the humoral immune system is dynamically altered following SCI, and that time after injury and the injury level per se are important considerations for future basic and translational investigations.

Materials and Methods

Mice and injury

Age-matched 5- to 7-wk-old female C57BL/6 mice were purchased from the National Cancer Institute (Bethesda, MD). All procedures were approved by the University of California at Irvine Institutional Animal Care and Use Committee. Mice were initially anesthetized with tribromoethanol (Avertin; 0.5 ml/20 g); when supplemental anesthesia was required, one-fourth of the original dose was given. Body temperature was maintained by placing mice on a water-circulating jacketed heating pad at 37 ± 0.5°C. The skin over the upper thoracic area was shaved and cleaned with a povidone-iodine (Betadine) solution. Using aseptic techniques, the skin was incised and connective and muscle tissues were bluntly dissected to expose vertebral bodies T3 or T9. A laminectomy of a single vertebral lamina was performed at T2–T3 or T9–T11 to expose the dorsal spinal cord. Experimental bilateral crush injury was performed using forceps (Dumont no. 5) placed on either side of exposed spinal cord following laminectomy. The points of the forceps were then brought together, held for 1 s, and released. The complete bilateral crush injury results in loss of motor function caudal to the injury site. The crush injury produces complete paralysis of the hindlimbs and mice do not recover the ability to walk (11). Therefore, hindlimb motor recovery behavioral assessment was not conducted for our studies. Incomplete lesions were identified on days 0 and 27 postinjury (following recovery from surgical anesthesia and prior to immunization, respectively) in mice displaying any degree of ankle, knee, and/or hip nonreflexive movement, and they were subsequently excluded from experimental analysis. After injury or laminectomy only, the muscles and skin were sutured separately and mice were given s.c. injections of lactated Ringer’s solution (1 ml/20 g) for hydration, buprenorphine (Buprenex; 0.05 mg/kg) for analgesia, and enrofloxacin (Baytril; 2.5 mg/kg) for prophylaxis against urinary tract infections. Uninjured mice did not undergo any surgery, but were anesthetized. Mice were placed in cages with F1 hybrid mice, with 50 μg NP15-CGG i.p. or received no treatment. Organs were collected on a BD LSR II flow cytometer (BD Biosciences) and analyzed with FlowJo software (Tree Star).

Corticosterone enzyme immunoassay

All blood collection by cardiac puncture occurred following euthanasia with anesthetic, and we consistently performed these procedures at the same time of day throughout these experiments. Previously it has been shown that nonmanipulated blood collection does not influence corticosterone levels in other nonmanipulated mice sharing the same environment (12); however, as a precautionary measure to avoid variable stress responses, blood collection from individual experimental groups (beginning with uninjured control mice) was done in a procedure room separate from where animals were housed. Plasma was isolated using buffered citrate from blood collected from each mouse postmortem, and corticosterone levels were assessed by ELISA (Immunodiagnostic Systems).

Histological analysis

Spinal columns were dissected from experimentally injured mice and postfixed in 4% paraformaldehyde overnight. Prior to spinal cord extraction from column, the thoracic vertebral location of the laminectomized region was recorded. Spinal cords were cryoprotected in 20% sucrose and embedded in OCT (Tissue-Tek). Eight-micrometer-thick sagittal sections were stained with H&E and visualized using a bright field microscope. Spleens were immersed in OCT and flash frozen using 2-methylbutane cooled with liquid nitrogen. Seven-micrometer sections were fixed with cold acetone and stored at −20°C. Prior to staining, the sections were rehydrated in 1× PBS, blocked with 10% goat serum, and stained with murine-reactive Abs: AF647-anti-IgD (eBioscience), rhodamine-anti-IgM F(ab')2 (SouthernBiotech), and AF647-anti-CD3ε (eBioscience). Sections were mounted using BioMed Gel Mount (Electron Microscopy Sciences) and were visualized on an LSM-510 Meta confocal microscope (Zeiss).

Flow cytometry

Splenocytes and BM were harvested and stained using the following murine-reactive Abs: allophycocyanin-Cy7-anti-CD19 (BD Biosciences), FITC-anti-B220 (BD Biosciences), eFluor 450-anti-CD21/23 (eBioscience), PE-anti-CD23 (BD Biosciences), PE-Cy7-anti-IgM (BD Biosciences), Qdot 705-streptavidin (Invitrogen), allophycocyanin-anti-AA4.1 (eBioscience), AF700-anti-B220 (eBioscience), FITC-anti-Lambda (SouthernBiotech), PE-Cy5-anti-CD4 (BD Biosciences), PE-Cy5-anti-CD8 (BD Biosciences), PE-Cy5-anti-Gr1 (eBioscience), PE-Cy5-anti-F4/80 (eBioscience), peanut agglutinin (PNA) conjugated to FITC (Vector Laboratories), eFluor 450-anti-IgD (eBioscience), PE-Cy7-anti-Fas (BD Biosciences). PE-Cy5.5-anti-CD21/23 was donated by D. Allman (University of Pennsylvania). NP was conjugated to allophycocyanin and Qdot 655 was conjugated to anti-Kappa (SouthernBiotech) in-house. PE was used for identification of NP-specific responders, intracellular staining was performed using a Fix and Perm kit (Caltag Laboratories) according to the manufacturer’s protocol and stained with reagents to detect NP, Ig, and IgG. For identification of surface NP+ germinal center (GC) B cells, we conducted staining on live nonpermeabilized splenocytes. Live/dead discrimination was assessed using either DAPI (Invitrogen) or Live/Dead Fixable Aqua (Invitrogen). Doublet discrimination was performed by forward scatter/side scatter width versus height analysis. Total cell numbers were calculated by multiplying the frequency of gated cells among live singlets by the total number of live cells harvested. Data were collected on a BD LSR II flow cytometer (BD Biosciences) and analyzed with FlowJo software (Tree Star).

NP-specific ELISA/ELISPOTs

Plates were coated with either 10 μg/ml NP15-CGG or NP15-BSA in 100 mM bicarbonate buffer and blocked with PBS containing 2% BSA. For ELISA, sera were incubated for 2 h at 37°C/5.5% CO2. NP-specific IgG1 or IgM standard was a gift from Dr. Garnett Kelsoe (Duke University, Durham, NC). Detection was conducted using HRP-conjugated goat anti-mouse IgG1 or IgM (SouthernBiotech) with a tetramethylbenzidine substrate kit (BD Biosciences) and color development was quantified using EMax (Molecular Devices). For ELISPOTs, cell suspensions containing 1 × 106 cells were incubated for 4 h at 37°C and developed with biotin-conjugated anti-mouse IgM or IgG1 (SouthernBiotech) followed by ExtrAvidin-alkaline phosphatase using NBT/5-bromo-4-chloro-3-indolyl potassium sulfate and analyzed at 14 d after immunization. For secondary immunizations, mice were immunized i.p. with 50 μg NP15-CGG 5 d prior to injury. Twenty-eight days postinjury, mice were either boosted with 50 μg NP15-CGG i.p. or received no treatment. Organs were harvested 7 d after secondary immunization.

Ags and immunizations

Primary immunizations with NP conjugated to protein or carbohydrate Ag were conducted after 28 d postinjury. For primary TI type 2 responses, mice were immunized i.p. with 50 μg NP15-CGG in FBS for flow cytometry and 4-hydroxy-3-nitrophenyl acetyl (NP)-specific ELISPOT analyses. Serum was frozen and shipped on dry ice for quantification of NP-specific Abs.

ELISPOT analyses. Serum was frozen and shipped on dry ice for quantification of NP-specific Abs.
phosphate substrate (Sigma-Aldrich). Color development was terminated with 1 M NaH₂PO₄ and spots were enumerated on a CTL ImmunoSpot reader (Cellular Technologies).

**Data analyses and statistics**

One-way ANOVA with a Dunnett post hoc analysis was performed with GraphPad Prism (GraphPad Software). Comparisons were made between injured groups and uninjured control groups, between SCI groups and their respective laminectomy control groups, and between T9 and T3 SCI groups.

**Results**

**Splenic architecture is preserved after spinal cord injury**

Most splenic sympathetic innervation derives from midthoracic levels, and thus injury at or above this region will result in loss of supraspinal control and decentralized sympathetic activity (13, 14) (depicted in Supplemental Fig. 1A). Accordingly, the effects of SCI on humoral immune function were assessed using a previously established model of injury above the site of splenic innervation, that is, T3 crush injury (9, 10). As controls, we used either uninjured mice, mice that received a crush injury at T9, a level at which splenic innervation is largely intact, or mice that received laminectomy surgery without crush injury. Postmortem histological analysis of thoracic vertebra from T3- and T9-injured mice was routinely performed to confirm injury location and complete crush (Supplemental Fig. 1B, 1C). The lesions in injured mice at 1 wk postinjury were qualitatively similar to previously described crush SCI in C57BL/6 mice (15). Importantly, crush injury results in no white matter sparing and produces complete paralysis of the hindlimbs and loss of the ability to walk (11). Additionally, T3 SCI was accompanied by a decrease in splenic weight as reported previously (9, 10). Immunohistologic evaluations at day 28 postinjury revealed that splenic microanatomy was preserved, including the T cell-rich periarterial lymphoid sheaths and adjacent IgD⁺IgM⁺ B cell follicles (Supplemental Fig. 1D). Thus, the general organization of the splenic white pulp is preserved following SCI.

**B cell genesis transiently ceases following SCI**

Despite the maintenance of lymphoid architecture, prior reports showed that T3 SCI adversely affects total splenic B cell numbers (9, 10, 16). Such reductions may reflect reduced B cell genesis, a direct loss of all or some mature B cell subsets, or both. To assess the relative contributions of these mechanisms, we examined developmental and mature B cell subsets in the BM (Fig. 1, Table I) and spleen (Fig. 2, Table II) during acute and chronic SCI. The gating strategies employed (17) resolve developmental and mature B cell subsets whose dynamics and functional characteristics are well established (reviewed in Refs. 18–20). Briefly, following Ig H and L chain gene rearrangements during the pro-B and pre-B cell stages, developing B cells in the BM enter the immature (IMM) B cell stage and then migrate to the periphery as TR B cells. All of these developmental subsets bear the AA4.1 marker and are further resolved according to the criteria shown in Figs. 1 and 2. In the BM, pre-B and pro-B cells lack surface IgM, whereas immature B cells are surface IgM⁺ (Fig 1). Splenic TR cells are all AA4.1⁺ and are further resolved into the TR1, TR2, and TR3 subsets based on differential CD23 and IgM expression levels (Fig. 2). Developing B cells fully transit these BM and splenic developmental stages during 4–6 d (17, 21–24), and thus all of
these subsets turnover quickly and therefore deplete rapidly when B lymphopoiesis stops. Following the TR differentiation stages, B cells complete maturation and enter either the FO or MZ pools.

### Table I. Numbers of BM B cell subsets during acute and chronic SCI

<table>
<thead>
<tr>
<th></th>
<th>Total Cells</th>
<th>Pro-/Pre-B Cells</th>
<th>Immature B Cells</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Uninjured</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Day 8 after injury</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T9 Lam</td>
<td>38.03 ± 8.7</td>
<td>1.06 ± 0.29</td>
<td>0.18 ± 0.05</td>
</tr>
<tr>
<td>T9 SCI</td>
<td>46.32 ± 8.88</td>
<td>1.07 ± 0.95</td>
<td>0.28 ± 0.37</td>
</tr>
<tr>
<td>T3 Lam</td>
<td>46.05 ± 5.60</td>
<td>1.85 ± 0.35</td>
<td>0.43 ± 0.13</td>
</tr>
<tr>
<td>T3 SCI</td>
<td>47.97 ± 9.49</td>
<td>0.68 ± 0.83</td>
<td>0.17 ± 0.12</td>
</tr>
<tr>
<td><strong>Day 28 after injury</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T9 Lam</td>
<td>34.61 ± 4.42</td>
<td>2.32 ± 0.6</td>
<td>0.84 ± 0.25</td>
</tr>
<tr>
<td>T9 SCI</td>
<td>47.39 ± 9.64</td>
<td>2.78 ± 0.92</td>
<td>0.88 ± 0.32</td>
</tr>
<tr>
<td>T3 Lam</td>
<td>36.5 ± 5.47</td>
<td>2.54 ± 0.44</td>
<td>0.95 ± 0.14</td>
</tr>
<tr>
<td>T3 SCI</td>
<td>52.83 ± 9.74</td>
<td>2.51 ± 0.98</td>
<td>0.81 ± 0.23</td>
</tr>
</tbody>
</table>

Mean ± SD of cells (×10^6) per hind limb, gated according to representative FACS plots shown in Fig. 1. Data have been pooled across six experiments for uninjured controls, one for laminectomies, and three for SCI at each level.

- *n* = 25 for uninjured.
- *n* = 8 for T9 Lam, *n* = 13 for T9 SCI, *n* = 8 for T3 Lam, and *n* = 12 for T3 SCI.
- *n* = 6 for T9 Lam, *n* = 13 for T9 SCI, *n* = 5 for T3 Lam and *n* = 13 for T3 SCI.

Denotes significant differences from uninjured control at *p* < 0.05.

Denotes significant differences from Lam controls at *p* < 0.05.

Lam, Laminectomy.

Both of these mature, preimmune subsets lack the AA4.1 marker and are distinguished by differential IgM and CD21/35 expression (Fig. 2) (17, 24, 25). Under normal conditions, most developing B cell progenitors in spleen is reduced following acute SCI. Representative FACS gating strategy to identify B cell subsets in the spleen at day 8 (A) and day 28 (B) after T3 SCI, T9 SCI, T3 laminectomy (Lam), T9 Lam, or in uninjured control mice. Contour plots show the mean frequency and SD of developing B220^+AA4.1^ and mature B220^+AA4.1^- splenic B cells (left panels), and further subsets of IgM^hi^CD23^+^ TR1, IgM^hi^CD23^+^ TR2, and IgM^lo^CD23^+^ TR3 developing B cells (middle panels, gates configured clockwise) as well as IgM^hi^CD21/35^hi^ MZ B and IgM^hi^CD21/35^lo^ FO B cells (right panels) among live singlets. At day 8 after SCI, *n* = 5 for uninjured, *n* = 8 for T9 Lam, *n* = 6 for T9 SCI, *n* = 8 for T3 Lam, and *n* = 5 for T3 SCI. At day 28 after SCI, *n* = 5 for uninjured, *n* = 7 for T9 Lam, *n* = 5 for T9 SCI, *n* = 7 for T3 Lam, and *n* = 6 for T3 SCI.
B cells adopt the FO fate, but differentiation skews to the MZ fate under conditions of B lymphopenia or reduced BM output (25). Unlike developing B cell subsets, MZ and FO B cells turn over slowly and persist for months to years (22, 26, 27), so their numbers are modestly affected by short-term perturbations in B cell genesis.

At day 8 after SCI, the proportions of all developmental B cell subsets were profoundly reduced in both T3 and T9 SCI compared with uninjured mice (Figs. 1A, 2A). These declines reflect significant decreases in the numbers of BM pro-B, pre-B, and immature B cells, as well as all splenic TR subsets (Figs. 1A, 2A, Tables I, II). In contrast to acute injury, BM developmental subsets were fully restored during chronic injury (Fig. 1B, Table I). The splenic TR subsets also recovered but were sometimes still mildly reduced at 28 d postinjury (Fig. 2B, Table II). Rapid depletion and subsequent reconstitution of B cell progenitor pools indicates that SCI engenders transient cessation of B cell genesis that is largely re-established within 28 d after injury.

Because B cell genesis resumes within 28 d after SCI, it is unlikely that sustained dysregulation of sympathetic activity underlies blunted B cell genesis during acute injury. Instead, they likely reflect injury-related stress or inflammation, both of which can yield depression of BM B cell genesis via corticosteroid hormones or inflammatory cytokines, respectively (3, 28, 29).

Consistent with this possibility, similar transient reductions in developing B cells were observed in mice receiving laminectomy injuries (Figs. 1, 2, Tables I, II), and serum corticosterone levels were elevated following SCI or laminectomy, regardless of injury location (Supplemental Table I). However, serum corticosterone returned to uninjured levels 28 d following laminectomy, yet remained elevated 28 d after T9 or T3 SCI, despite recovery of B cell genesis in all treatment groups. Accordingly, although elevated corticosterone may contribute to blocked B cell production during acute SCI, it is alone insufficient to mediate this effect and probably acts in concert with additional inhibitors of B cell genesis that are temporarily present following injury.

**FO, but not MZ, B cells are reduced during SCI**

We next addressed how acute and chronic SCI affect mature splenic B cell pools. For all experiments, FO B cell numbers were modestly reduced following acute or chronic SCI. These consistent reductions frequently, but not always, achieved statistical significance (Table II). In contrast, MZ B cell numbers were always either preserved or increased during both acute and chronic SCI (Table II). Variability in the degrees to which FO B cell numbers decreased and MZ B cell numbers expanded likely reflects a dynamic interplay of several factors. Foremost among these are the extent to which B lymphopoiesis is blunted and how quickly it is re-established, as these parameters will determine the degree of impact on FO B cell numbers and the associated skewing of cells into the MZ pool (25). Collectively, our findings extend prior observations demonstrating that reduced numbers of splenic B cells during acute SCI reflect a severe truncation of TR subsets, combined with a consistent but less profound depletion of FO, but not MZ, B cells (9). Moreover, we find that during chronic SCI, B lymphopoiesis has resumed, but mild reductions in TR and FO B cell numbers persist. Nonetheless, a large proportion of the mature B cell pool remains intact and, if functional, should be able to respond to antigenic challenge during chronic stages of SCI.

**The TI type 2 immune response is profoundly decreased after chronic T3 injury**

Despite the persistence of substantial mature B cell numbers, prior studies showed that acute SCI yields blunted primary TD Ab responses (9). Whether these defects extend to TI responses, as well as whether they continue during chronic injury, has not been determined. Accordingly, we examined NP-specific responses during chronic SCI. The NP-specific response in C57BL/6 mice is dominated by IgA+ B cells, and thus responding cells can be tracked based on both NP-binding and IgA expression (30). Additionally, numbers of NP-specific Ab-secreting cells (ASCs) and Ab concentrations can be assessed by ELISPOT and ELISA, respectively.

Using this model, we first tested whether chronic SCI affects TI type 2 responses using NP-conjugated to the carbohydrate polymer Ficoll (NP-Ficoll). MZ B cells are responsible for most of the TI type 2 response and, as their numbers are not reduced following SCI, any differences in response magnitude likely reflect altered functionality (31).

**Table II. Numbers of splenic B cell subsets during acute and chronic SCI**

<table>
<thead>
<tr>
<th></th>
<th>Total Cells</th>
<th>TR1</th>
<th>TR2</th>
<th>TR3</th>
<th>FO</th>
<th>MZ</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Uninjured</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T9 Lam</td>
<td>131.6 ± 26.2</td>
<td>2.7± 0.6</td>
<td>2.5± 0.8</td>
<td>2.3± 0.7</td>
<td>28.9± 5.4</td>
<td>3.2± 0.5</td>
</tr>
<tr>
<td>T9 SCI</td>
<td>104.3 ± 6.3</td>
<td>0.9± 0.1d</td>
<td>1.3± 0.2d</td>
<td>1.2± 0.2d</td>
<td>24.1± 3.0</td>
<td>2.9± 0.6</td>
</tr>
<tr>
<td>T3 Lam</td>
<td>111.1 ± 22.1</td>
<td>1.5± 0.9d</td>
<td>1.6± 0.7d</td>
<td>1.6± 0.5</td>
<td>21.2± 6.5</td>
<td>3.1± 1.9</td>
</tr>
<tr>
<td>T3 SCI</td>
<td>111.3 ± 18.5</td>
<td>0.3± 0.1d</td>
<td>0.7± 0.2d</td>
<td>0.7± 0.2d</td>
<td>20.2± 3.9d</td>
<td>2.5± 0.5</td>
</tr>
<tr>
<td><strong>Day 28 after injury</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T9 Lam</td>
<td>149.7± 32.9</td>
<td>3.8± 0.8d</td>
<td>2.6± 0.4</td>
<td>2.2± 0.4</td>
<td>30.4± 8.2</td>
<td>3.2± 0.7</td>
</tr>
<tr>
<td>T9 SCI</td>
<td>86.8 ± 12.5d</td>
<td>2.5± 0.6e</td>
<td>2.2± 0.6</td>
<td>2.0± 0.7</td>
<td>21.1± 4.0d</td>
<td>3.4± 0.4</td>
</tr>
<tr>
<td>T3 Lam</td>
<td>119 ± 22.2</td>
<td>3.5± 0.7</td>
<td>2.5± 0.5</td>
<td>2.0± 0.4</td>
<td>22.9± 4.6</td>
<td>2.9± 0.5</td>
</tr>
<tr>
<td>T3 SCI</td>
<td>93.6 ± 24.1d</td>
<td>1.6± 0.4d</td>
<td>1.8± 0.5</td>
<td>1.8± 1.0</td>
<td>22.3± 5.9</td>
<td>4.3± 1.3d</td>
</tr>
</tbody>
</table>

Number ± SD of cells (×10^6) per spleen, representative FACS plots shown in Fig. 2. Numbers shown are representative of three experiments at each postinjury time point. Data shown have been pooled across two experiments for uninjured controls, one for laminectomies, and one for SCI at each level.

*a* Denotes significant differences from uninjured control at *p* < 0.05.

*b* Denotes significant differences from laminectomy control at *p* < 0.05.

*c* Denotes significant differences from Lam controls at *p* < 0.05.

Lam, Laminectomy.
Primary TD responses are decreased during chronic T3 SCI

To extend studies examining acute SCI, we asked whether defects in TD responses would persist during chronic SCI. Therefore, mice were challenged 28 d after SCI with NP-CGG, and responding cells in the spleen and bone marrow were evaluated (Fig. 4A). NP-specific TD responses peak between 10 and 14 d postimmunization (33), and thus we assessed the responses at day 14. Compared to uninjured and T9-injured controls, there was a significant reduction in the frequency and number of splenic NP-IgG1+ B cells in T3-injured mice (representative staining; Fig. 4B, 4C, Supplemental Fig. 2A). Furthermore, both the number and frequency of NP-specific IgG1 ASCs were significantly reduced in the BM and spleen after T3, but not T9, injury when compared with uninjured mice (Fig. 4D, Supplemental Fig. 2B). Consistent with a defect in the generation of these cells, serum levels of anti–NP-specific IgG1, but not IgM, were also significantly reduced in T3-injured mice compared with uninjured controls (Fig. 4E). In sum, chronic T3 injury severely diminishes the magnitude of primary TD responses.

Affinity maturation is intact during chronic SCI despite reductions in GC B cells and total high-affinity Ab

Effective TD responses require the formation of GCs, where B cells undergo class switch recombination, somatic hypermutation, and selection to yield the high-affinity, isotype-switched B cell clones that populate the memory and long-lived ASC compartments (34). Because the magnitude of TD responses was severely reduced during chronic SCI, we assessed whether the GC reaction was also compromised. NP-specific GC B cells can be identified cytofluorometrically by gating on activated B cells (IgD−CD19+) that bind NP and PNA and express high levels of Fas (representative gating strategy is shown in Fig. 5A) (35–37). At 14 d after immunization, T3-injured mice had significantly reduced numbers of NP-specific splenic GC B cells compared with uninjured mice (Fig. 5B).

Diminished GC B cell numbers could reflect either the loss of total responding cells, and therefore a loss of B cells initiating the GC fate, or an alteration to GC function resulting in the premature termination of GC B cell differentiation. Previous studies have established that whereas cells with both low and high affinity for NP bind to highly substituted NP-BSA (NP33), only those with high affinity for NP bind to lowly substituted NP-BSA (NP4) (33, 38). In this way, both total and high-affinity NP-specific Ab can be detected via ELISpot and ELISA. Therefore, to examine whether reductions in GC B cells resulted in a loss of GC function, we assessed the relative affinity of responding ASCs and Abs from injured mice. Although the numbers and frequencies of high-affinity IgG1 ASCs in the spleen and BM were significantly reduced in T3-injured mice compared with uninjured mice, they were nonetheless detectable (Fig. 5C, Supplemental Fig. 2C). Similarly, ELISA revealed that both chronic T3 and T9 SCI mice had high-affinity NP-specific IgG1, albeit at significantly reduced levels compared with uninjured mice (Fig. 5D). The presence of high-affinity NP-specific ASCs and Abs suggests that the somatic hypermutation and selection processes required for affinity maturation are indeed intact following SCI. To confirm that the loss in total GC B cells and high-affinity NP-specific ASCs was due primarily to a paucity of responding B cells, we compared the ratio of high-affinity/total IgG1 ASCs and found that they were comparable to uninjured mice (Fig. 5E). Taken together, these observations show that the affinity maturation process per se is intact during chronic SCI, but diminished numbers of responding cells yield fewer high-affinity effectors.

Pre-existing B cell memory in the spleen is unaffected by chronic SCI

Memory B cells and long-lived plasma cells formed during primary humoral responses provide protective immunity to subsequent Ag exposures and are the mechanistic basis for most current vaccines (39). Accordingly, a potential risk facing those with SCI is loss of acquired immunity from prior natural immunizations or vaccinations. Thus, we addressed the affects of chronic SCI on established B cell memory and the ability to mount secondary responses. We immunized mice with NP-CGG, waited 54 d for the primary response to

---

**Figure 3.** Humoral responses to TI type 2 Ags are decreased during chronic T3 SCI. (A) Experimental design for NP-Ficoll immunization: 28 d after SCI or postlamincetomy, mice were immunized with NP-Ficoll and the splenic tissue was analyzed at day 4.5. (B) Representative FACS gating strategy to identify NP-specific B cells. Dot plots show the frequency of Aqua−CD4−CD8−F4/80−Gr1−IgM−IgA−NP+ responding B cells among live singlets. (C) Total number of NP-specific B cells. (D) Total number of NP-specific IgM ASCs. For all data sets, n = 5 for uninjured, n = 7 for T9 laminectomy (Lam), n = 6 for T9 SCI, n = 7 for T3 SCI, and n = 8 for T3 *p < 0.05, **p < 0.01.
wane while allowing memory pools to establish (33, 40), and then induced SCI (Fig. 6A). Twenty-eight days postinjury, one cohort of mice was analyzed without further treatment (designated as resting memory) and the second cohort was boosted with NP-CGG (designated as boosted memory). In the latter group, high-affinity ASCs were assessed 7 d postimmunization, at a time point well before new responders have undergone affinity maturation (33). Strikingly, we found no differences between the treatment groups in either the frequency or total number of high-affinity splenic ASCs (Fig. 6B) or the concentration of high-affinity Abs (Fig. 6C) in either the resting or the boosted memory responses. Thus, we conclude that despite the impaired capacity to mount primary TD responses following SCI, previously established humoral memory and the ability to respond to secondary challenge remain intact.

Discussion

These studies probe the impact of acute and chronic SCI on B lymphopoiesis, preimmune B cell homeostasis, and the capacity to mount primary or memory humoral responses. Our results reveal a transient cessation of BM B lymphopoiesis during acute T3 or T9 SCI that resolves within 4 wk injury. Consistent with this decreased BM output, splenic TR B cell numbers show a corresponding transient decline and resurgence. FO B cell numbers were consistently but mildly reduced following injury, and were most severely affected following T3 injury. In contrast, MZ B cell numbers were either unaffected or increased. Despite the presence of these mature preimmune B cells, both TI type 2 and primary TD humoral immune responses were profoundly reduced during chronic T3 injury. Finally, we find that SCI affects neither existing memory B cell numbers nor their ability to respond upon rechallenge. Collectively, these findings reveal previously unappreciated temporal and functional complexity in the impact of SCI on B cell compartments and humoral immunity.

The transient cessation of B lymphopoiesis following SCI likely reflects a combination of mechanisms. Stress hormones can both inhibit B lymphopoiesis and favor myelopoiesis, and they are elevated during acute injury (3, 9). However, B lymphopoiesis recovered within 4 wk despite continued elevation of corticosterone in chronically injured mice. These observations are consistent with those in chronic SCI patients, who have normal numbers of bone marrow lymphocytes despite elevated stress hormones (41, 42). Accordingly, transiently reduced B lymphopoiesis likely reflects additional or alternative mechanisms. Similar temporary reductions in B lymphopoiesis occur during inflammatory responses following immunization or infection (28, 29) and are associated with increases in proinflammatory cytokines such as TNF-α, IL-1β, or IFN-α/β (43–45). Inasmuch as these cytokines transiently increase at the site of spinal injury (46), it is tempting...
to speculate that both inflammatory cytokines and stress hormones impact B lymphopoiesis during acute injury. B cell progenitors from T3, but not T9, SCI mice were significantly decreased when compared with laminectomy controls, and thus it remains possible that injury level impacts the extent to which B cell genesis is inhibited. However, we favor the notion that this reflects different levels of stress and inflammation, rather than a loss of sympathetic regulation, for several reasons. First, B cell genesis was significantly reduced in both T9 and T3 injured mice compared with uninjured controls, and both showed restoration after 4 wk.

**FIGURE 5.** GC B cells and high-affinity ASCs are reduced in T3-injured mice after TD immunization. (A) Representative FACS plots for identification of NP-specific GC B cells in uninjured mice (CD19⁺CD4⁻CD8⁻F4/80⁻Gr1⁻IgD⁻PNA⁺NP⁺Fas⁺). Numbers shown in each dot plot are percentages of each population within the parent gate. (B) The absolute number of GC B cells in the spleen (n = 4–5 mice/group). (C) Total number of high-affinity NP-specific IgG1 ASCs in BM and spleen. (D) Serum concentrations of NP-specific high-affinity IgG1 Ab above nonimmunized controls. (E) Affinity maturation within the spleen as determined by the ratio of high-affinity to total IgG1 ASCs (Fig. 4D); For (C)–(E), n = 5 for uninjured, n = 5 for T9 SCI, and n = 9 for T3 SCI. Data are representative of two experiments. **p < 0.01.

**FIGURE 6.** Secondary humoral responses are intact following chronic SCI. (A) Experimental design for assessment of secondary TD responses in injured and uninjured mice. Mice were immunized 54 d prior to SCI, and then 28 d after injury resting (●) and boosted (○) memory responses were assessed. (B) The frequency per million and total number of splenic high-affinity IgG1 ASCs and (C) high-affinity IgG1 anti-NP Ab above nonimmunized controls both before and after secondary challenge are shown (n = 4–5 mice/group). Data are representative of two experiments.
something that would not be predicted to occur if it were due to the disruption of supraspinal sympathetic regulation. Moreover, we also observed reductions in B cell genesis following laminec- tomy, further supporting the notion that stress and inflammation associated with injury per se, rather than supraspinal regulation, causes the blunting of B lymphopoesis.

Although consistent with prior studies demonstrating reductions in total CD19+ splenic B cells 3 d after T3 SCI (9), the detailed subsetting in this study reveals that multiple factors contribute to this overall phenomenon. Thus, reductions in the TR pools contribute substantially to initial splenic B cell losses, reflecting truncated BM output. Likewise, there is a reduction in the number of mature FO B cells following acute injury. Despite blunted B cell genesis, a large fraction of FO B cells and all MZ B cells remain, consistent with their comparatively slow turnover rates (22). Surprisingly, although BM output resumes, steady-state TR and FO B cell numbers are variably reduced during chronic injury (Table II). These continued reductions in splenic B cell populations 28 d after injury may reflect the severity of initial loss of B cell genesis and consequently differing rates of its restoration. Alternatively, reduced numbers of splenic B cell subsets are consistent with prior findings that acute T3 SCI increases the proportion of apoptotic cells found among splenic lymphocytes (9, 16). Because the ability to bind the cytokine B lymphocyte stimulator (BLYsS, also termed BAFF) through BLyS receptor 3 (BR3) is essential for FO B cell survival (47–49), we assayed BR3 levels on FO B cells and found no difference between uninjured and injured mice (data not shown). The preservation of MZ B cell numbers under all conditions is consistent with the selective preservation of this subset even under B lymphopenic conditions (25). This likely reflects both a larger proportion of TR B cells assuming an MZ B fate as they mature, as well as the acquisition of MZ B cell characteristics by FO B cells driven by B lympho- penia. Taken together, these findings strongly suggest that SCI has a direct affect on peripheral B cell homeostasis.

Despite differential effects on mature, quiescent B cell pools, chronic T3 injury clearly impacts the magnitude of both TI and TD primary responses, which are dominated by MZ or FO B cells, respectively (31). The number of MZ B cells was not reduced after T3 injury, and thus simple reductions in numbers cannot explain the diminished TI responses. Whether SCI also negatively affects B1 B cells, which can contribute to TI immunity (50), or other cell types such as bystander T cells, which contribute to the magnitude of TI type 2 humoral responses, will be an important avenue for future exploration. Consistent with observations made during the acute phase of T3 SCI (9), the inability to mount optimal TD immune responses persisted during chronic injury, likely in part due to the reduced numbers of FO B cells observed. Alternatively, decreased FO B cell responsiveness may be due to SCI-induced impairments to T cell responses as reported (9, 10). Nevertheless, affinity maturation is unaffected by SCI, indicating that the process of somatic hypermutation and selection of high-affinity B cells within the GC reaction are largely independent of neuro- nal regulation. Because these key features of TD responses remain intact, strategies to induce protective humoral immunity after SCI might best focus on augmenting the frequency and expansion of initially responding cells to achieve protection. Alternatively, TI Ags will remain problematic, since prior memory for such Ags will not exist, and TI responses are persistently and severely compromised after T3 injury. Consequently, the use of conjugate vaccines, which couple TI epitopes to proteins to enable TD responses (51), might prove effective.

Acknowledgments
We thank the Reeve–Irving Research Center and the Roman Reed Spinal Cord Research Program for facility and personnel support.

Disclosures
The authors have no conflicts of interest.

References
5266 IMPACT OF CHRONIC SPINAL CORD INJURY ON HUMORAL IMMUNITY
87: 4781–4784.
7: 40–59.
1123–1130.
191: 2113–2120.
298: 377–379.
172: 1681–1689.
78: 361–366.
236: 139–150.
126: 870–877.
199: 47–58.
1: 31–36.
377–379.
2134–1323.
287–290.
178: 79–87.
2: 709–721.
4: 617–629.
237: 3783–3791.
110: 1409–1421.
2001. Character-
terization of the central nervous system innervation of the rat spleen using viral
degeneration and wound healing following spinal cord injury in various strains of
2: 323–335.
B cell maturation, II: Heat-stable antigenabh splenic B cells are an immature
developmental intermediate in the production of long-lived marrow-derived
Rolink, A. G., I. Andersson, and F. Melchers. 1998. Characterization of im-
mature B cells by a novel monoclonal antibody, by turnover and by mitogen
Lindsley, R. C., M. Thomas, B. Srivastava, and D. Allman. 2007. Generation of
peripheral B cells occurs via two spatially and temporally distinct pathways.
1234.
Forster, I., and K. Rajewsky. 1990. The bulk of the peripheral B-cell pool in mice
is stable and not rapidly renewed from the bone marrow. Proc. Natl. Acad. Sci.
USA 87: 4781–4784.
2000. Immunization and infection change the number of recombination acti-
vation gene (RAG)-expressing B cells in the periphery by altering immature
Ueda, Y., K. Yang, S. J. Foster, M. Kondo, and G. Kelsoe. 2004. Inflammation
controls B lymphopoiesis by regulating chemokine CXCL12 expression. J. Exp.
Dorshkind, K. 1988. IL-1 inhibitors B cell differentiation in long term bone
Lin, Q., C. Dong, and M. D. Cooper. 1998. Impairment of T and B cell devel-
Pineau, I., and S. Lacroix. 2007. Proinflammatory cytokine synthesis in the in-
jured mouse spinal cord: multiphasic expression pattern and identification of the
Harless, S. M., V. M. Lentz, A. P. Sah, B. L. Hsu, K. Clise-Dwyer, D. M. Hilbert,
C. E. Hayes, and M. P. Cancro. 2001. Competition for BllyS-mediated signaling
Miller, D. J., and C. E. Hayes. 1991. Phenotypic and genetic characterization of a
21: 1123–1130.
Schneider, P., F. MacKay, V. Steiner, K. Hofmann, J. L. Bodmer, N. Hollar,
ligand of the tumor necrosis factor family, stimulates B cell growth.
Martin, F., A. M. Oliver, and J. F. Kearney. 2001. Marginal zone and B1 B cells
unite in the early response against T-independent blood-borne particulate anti-
Lesinski, G. B., and M. A. Westerink. 2001. Novel vaccine strategies to
Supplemental Figure 1: Modeling SCI in mice and evaluation of splenic architecture following injury. (A) Diagram showing injury at thoracic level T3 or T9, and resulting loss of supraspinal sympathetic outflow to the spleen following T3-SCI. (B) Experimental injury location was confirmed by post-mortem analysis of thoracic laminectomy region. (C) Hematoxylin and eosin-stained sections of mice at day 8 post-SCI (4x sagittal section). (D) Confocal micrographs of splenic architecture depicting intact T cell rich PALS region (CD3+) and surrounding B cell follicle (IgD+ IgM+). Histological analyses are representative of 3 mice per group.

Supplementary Figure 2: Frequency/million ASCs or responding B cells during TD primary immune responses. Mice were immunized 28 days post-injury and responses in the bone marrow (2 hind limbs) and/or spleen were assessed. (A) Splenic NP-specific B cells as determined by FACS at d14 post-immunization with NP-CGG (B,C) Total (B) or High affinity (C) IgG1 ASCs present in the spleen and BM assessed at d14 post-NP-CGG-immunization. For all data sets, n=5 for un-injured, n=5 for T9-SCI, and n=9 for T3-SCI. ** denotes significance at p<0.01 and * denotes significance at 0.01≤p<0.05.
Oropallo et al. Supplemental Figure 1

A

Thoracic Injury Location

Paravertebral Ganglia

Celiac Ganglion

SPLEEN

B

Thoracic Injury Level

1 2 3 4 5 6 7 8 9 10 11 12 13

C

T9-SCI

T3-SCI

D

28DPI

Un-injured

T9-SCI

T3-SCI

Primary TD Humoral response study

Secondary TD Humoral response study

B cell subsets study d8 post SCI

B cell subsets study d28 post SCI

TI-2 Humoral response study

CD3  IgM  IgD
Oropallo et al  Supplemental Figure 2

A

B

C

NP+Igλ+ cells/10^6

anti-NP IgG1 ASCs /10^6

High Affinity Anti-NP IgG1 ASCs /10^6
Supplemental Table I: Corticosterone plasma levels following acute and chronic SCI

<table>
<thead>
<tr>
<th>Experimental Group φ</th>
<th>Day Post-SCI</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>8</td>
<td>28</td>
</tr>
<tr>
<td>Un-injured</td>
<td>68.98±26.79 (n=5)</td>
<td>120.68±28.54 (n=5)</td>
</tr>
<tr>
<td>T9-Laminectomy</td>
<td>399.9 ± 66.89a (n=8)</td>
<td>123.39 ± 23.79 (n=7)</td>
</tr>
<tr>
<td>T9-SCI</td>
<td>409.5 ± 74.91a (n=6)</td>
<td>368.11 ± 89.57ab (n=5)</td>
</tr>
<tr>
<td>T3-Laminectomy</td>
<td>278.28 ± 73.5 (n=8)</td>
<td>131.68 ± 25.86 (n=7)</td>
</tr>
<tr>
<td>T3-SCI</td>
<td>337.56 ± 65.14a (n=6)</td>
<td>498.13 ± 66.89ab (n=6)</td>
</tr>
</tbody>
</table>

φValues represent the means ± SEM of plasma corticosterone levels measured in ng/ml

aDenotes significant difference from un-injured control at p<0.05

bDenotes significant difference from respective laminectomy control at p<0.05